Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Why is Hainan Huluwa Pharmaceutical Group Co., Ltd. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -6.31% and Operating profit at -188.94% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

With a fall in Net Sales of -49.56%, the company declared Very Negative results in Sep 25

The company has declared negative results for the last 3 consecutive quarters
INTEREST(HY) At CNY 20.07 MM has Grown at 26.51%
NET SALES(Q) At CNY 175.05 MM has Fallen at -49.56%
PRE-TAX PROFIT(Q) At CNY -11.16 MM has Fallen at -957.39%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -57.46%, its profits have fallen by -473.3%
At the current price, the company has a high dividend yield of 0

Below par performance in long term as well as near term

Along with generating -57.46% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hainan Huluwa Pharmaceutical Group Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Hainan Huluwa Pharmaceutical Group Co., Ltd.

-58.47%

-0.82

39.86%

China Shanghai Composite

15.17%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.31%

EBIT Growth (5y)

-188.94%

EBIT to Interest (avg)

20.78

Debt to EBITDA (avg)

2.79

Net Debt to Equity (avg)

1.54

Sales to Capital Employed (avg)

0.70

Tax Ratio

2.33%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

16.66%

ROE (avg)

7.90%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.04

EV to EBIT

-13.37

EV to EBITDA

-18.97

EV to Capital Employed

2.68

EV to Sales

4.29

PEG Ratio

Dividend Yield

ROCE (Latest)

-20.07%

ROE (Latest)

-49.20%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at CNY -35.56 MM

-45What is not working for the Company

INTEREST(HY)

At CNY 20.07 MM has Grown at 26.51%

NET SALES(Q)

At CNY 175.05 MM has Fallen at -49.56%

PRE-TAX PROFIT(Q)

At CNY -11.16 MM has Fallen at -957.39%

NET PROFIT(Q)

At CNY -13.62 MM has Fallen at -365.37%

ROCE(HY)

Lowest at -40.09%

DEBT-EQUITY RATIO (HY)

Highest at 164.41 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.8 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.51 times

RAW MATERIAL COST(Y)

Grown by 24.22% (YoY

CASH AND EQV(HY)

Lowest at CNY 279.46 MM

Here's what is not working for Hainan Huluwa Pharmaceutical Group Co., Ltd.

Interest

At CNY 20.07 MM has Grown at 26.51%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 175.05 MM has Fallen at -49.56%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit

At CNY -11.16 MM has Fallen at -957.39%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -13.62 MM has Fallen at -365.37%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Debt-Equity Ratio

Highest at 164.41 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.8 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 1.51 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Cash and Eqv

Lowest at CNY 279.46 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 24.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales